While Alto Neuroscience Inc. has overperformed by 2.48%, investors are advised to look at stock chart patterns for technical insight.
On February 27, 2024, William Blair started tracking Alto Neuroscience Inc. (NYSE: ANRO) recommending Outperform. A report published by TD Cowen on February 27, 2024, Initiated its previous ‘Outperform’ rating for ANRO. Stifel also rated ANRO shares as ‘Buy’, setting a target price of $32 on the company’s shares in an initiating report dated February 27, 2024. Robert W. Baird Initiated an Outperform rating on February 27, 2024, and assigned a price target of $32. Jefferies initiated its ‘Buy’ rating for ANRO, as published in its report on February 27, 2024.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Alto Neuroscience Inc. (ANRO)
One of the most important indicators of Alto Neuroscience Inc.’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. Taking into account the quick ratio of the company, currently set at 19.85, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and ANRO is recording 186.12K average volume. On a monthly basis, the volatility of the stock is set at 8.32%, whereas on a weekly basis, it is put at 5.60%, with a gain of 12.27% over the past seven days. Furthermore, long-term investors anticipate a median target price of $34.27, showing growth from the present price of $12.81, which can serve as yet another indication of whether ANRO is worth investing in or should be passed over.
How Do You Analyze Alto Neuroscience Inc. Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 17.79%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 68.21% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ANRO shares are owned by institutional investors to the tune of 68.21% at present.
